Gyre Therapeutics annual gross margin
2022
2023
2024
Gyre Therapeutics Gross Margin Growth & History (GYRE)
Gyre Therapeutics's gross margin was 96.33% for fiscal 2024.
View full Gyre Therapeutics company overviewGyre Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 96.33% | +0.41 pp |
| 2023 | 2023-12-31 | 95.91% | +0.60 pp |
| 2022 | 2022-12-31 | 95.31% | — |
Gyre Therapeutics quarterly gross margin
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | 94.67% | −1.57 pp |
| Q2 2025 | 2025-06-30 | 86.16% | −10.78 pp |
| Q1 2025 | 2025-03-31 | 95.95% | −0.45 pp |
| Q4 2024 | 2024-12-31 | 95.78% | +0.38 pp |
| Q3 2024 | 2024-09-30 | 96.24% | −0.06 pp |
| Q2 2024 | 2024-06-30 | 96.95% | +0.62 pp |
| Q1 2024 | 2024-03-31 | 96.40% | +0.91 pp |
| Q4 2023 | 2023-12-31 | 95.40% | — |
| Q3 2023 | 2023-09-30 | 96.30% | — |
| Q2 2023 | 2023-06-30 | 96.33% | — |
| Q1 2023 | 2023-03-31 | 95.49% | — |
Gyre Therapeutics gross margin trends
Across the available reported history, Gyre Therapeutics's gross margin increased from 95.91% to 96.33%, a change of +0.41 percentage points. The latest reported quarter, Q3 2025, shows 94.67%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gyre Therapeutics filings at SEC.gov ↗